Alnylam reports Q2 2026 revenue of $1.172 billion, with Amvuttra reaching $1.01 billion in quarterly revenue

Alnylam Pharmaceuticals/Amvuttra (vutrisiran)

Alnylam announced record second-quarter results with Amvuttra generating $1.01 billion in global net product revenue, a 106% increase year-over-year and the first time the drug exceeded $1 billion in a single quarter. The company revised full-year 2026 TTR revenue guidance to $4.2–$4.5 billion as pent-up demand from newly diagnosed patients normalizes.